In a preclinical study, it was established that the blockade of CD112R alone or together with TIGIT-blockade enhances the trastuzumab-triggered antitumor response in human NK cells and improves the efficacy of trastuzumab therapy for breast cancer.104,160,164 This finding suggests that CD112R on NK cells may be a potential target for breast cancer treatment in the future, although its efficacy and safety remain to be further verified through animal experiments and clinical trials. This evidence concerns the gene PVRIG and breast cancer.